Cargando…

Joint recommendations for a total services account as a factor in simplifying contracts

The objective of clinical trials is to transfer findings gained from basic research to patients and to result in innovative treatment approaches. Along with basic research, results from clinical trials thus represent a core area of medical advances. As a location for clinical trials, Germany is curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruns, Insa, Schade-Brittinger, Carmen, Wissing, Frank, Ruppert, Thorsten, Trillsch, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: German Medical Science GMS Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838650/
https://www.ncbi.nlm.nih.gov/pubmed/31728135
http://dx.doi.org/10.3205/000276
_version_ 1783467260251209728
author Bruns, Insa
Schade-Brittinger, Carmen
Wissing, Frank
Ruppert, Thorsten
Trillsch, Martin
author_facet Bruns, Insa
Schade-Brittinger, Carmen
Wissing, Frank
Ruppert, Thorsten
Trillsch, Martin
author_sort Bruns, Insa
collection PubMed
description The objective of clinical trials is to transfer findings gained from basic research to patients and to result in innovative treatment approaches. Along with basic research, results from clinical trials thus represent a core area of medical advances. As a location for clinical trials, Germany is currently well-positioned and internationally competitive. This is evident in its position as No. 2 in Europe and No. 3 worldwide – behind the US and UK – in clinical trials of pharmaceuticals [1]. Maintaining and further improving this favorable positioning as a location for clinical trials is in the mutual interest of all parties involved in the field of clinical research, patients, trial sites and sponsors of clinical trials. For patients, clinical trials offer opportunities to gain early access to innovative therapy options. In addition to the scientific interest from medical faculties, clinical research is thereby an important aspect for university clinics in Germany as they fulfill their medical care mandate. Their involvement in clinical trials gives physicians the ability to gather experience with new treatment approaches at an early stage and to pass this know-how on to their patients. A location’s clinical research is thus an important competitive factor in terms of international comparison as well. Industry likewise benefits from the favorable research infrastructure in Germany, which provides rapid patient recruitment and outstanding quality of results obtained and can thus contribute to the early approval of new drugs. From the perspective of the authors, it is therefore essential that Germany continues to remain competitive as a location for conducting clinical trials, precisely because the number of clinical trials is decreasing overall. Companies themselves are in international competition internally and externally, which often creates a certain pressure on trial preparation and thus on the start of a clinical trial. To ensure that a clinical trial can begin early, it is essential that contracts related to the trial are concluded quickly and simply, including remuneration for participants and full, transparent and comprehensible coverage of content for the business relationship. The swift agreement of key contractual and budgetary aspects is therefore in the interest of everyone involved. Against this backdrop, the German Association of Medical Faculties (MFT), the German Association of Academic Medical Centers (VUD), the Coordination Center for Clinical Studies (KKS-Netzwerk) and the German Association of Research-Based Pharmaceutical Companies (vfa) have held joint discussions regarding an important aspect of the contract negotiations – the cost consideration of clinical trials. As a result of these talks, these organizations have developed and published joint “Recommendations for the preparation of a total services calculation for remuneration related to the conduct of a clinical trial in a trial center” [2], [3]. The parties concerned share the conviction that, against the backdrops described, it would be helpful if the potential contract partners had access to recommendations that offer examples of constantly recurring cost positions in order to more precisely determine remuneration related to the conduct of a clinical trial. This article explains how the “Recommendations for the preparation of a total services calculation for remuneration related to the conduct of a clinical trial in a trial center” [2], [3] were developed and provides an overview of their content.
format Online
Article
Text
id pubmed-6838650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher German Medical Science GMS Publishing House
record_format MEDLINE/PubMed
spelling pubmed-68386502019-11-14 Joint recommendations for a total services account as a factor in simplifying contracts Bruns, Insa Schade-Brittinger, Carmen Wissing, Frank Ruppert, Thorsten Trillsch, Martin Ger Med Sci Article The objective of clinical trials is to transfer findings gained from basic research to patients and to result in innovative treatment approaches. Along with basic research, results from clinical trials thus represent a core area of medical advances. As a location for clinical trials, Germany is currently well-positioned and internationally competitive. This is evident in its position as No. 2 in Europe and No. 3 worldwide – behind the US and UK – in clinical trials of pharmaceuticals [1]. Maintaining and further improving this favorable positioning as a location for clinical trials is in the mutual interest of all parties involved in the field of clinical research, patients, trial sites and sponsors of clinical trials. For patients, clinical trials offer opportunities to gain early access to innovative therapy options. In addition to the scientific interest from medical faculties, clinical research is thereby an important aspect for university clinics in Germany as they fulfill their medical care mandate. Their involvement in clinical trials gives physicians the ability to gather experience with new treatment approaches at an early stage and to pass this know-how on to their patients. A location’s clinical research is thus an important competitive factor in terms of international comparison as well. Industry likewise benefits from the favorable research infrastructure in Germany, which provides rapid patient recruitment and outstanding quality of results obtained and can thus contribute to the early approval of new drugs. From the perspective of the authors, it is therefore essential that Germany continues to remain competitive as a location for conducting clinical trials, precisely because the number of clinical trials is decreasing overall. Companies themselves are in international competition internally and externally, which often creates a certain pressure on trial preparation and thus on the start of a clinical trial. To ensure that a clinical trial can begin early, it is essential that contracts related to the trial are concluded quickly and simply, including remuneration for participants and full, transparent and comprehensible coverage of content for the business relationship. The swift agreement of key contractual and budgetary aspects is therefore in the interest of everyone involved. Against this backdrop, the German Association of Medical Faculties (MFT), the German Association of Academic Medical Centers (VUD), the Coordination Center for Clinical Studies (KKS-Netzwerk) and the German Association of Research-Based Pharmaceutical Companies (vfa) have held joint discussions regarding an important aspect of the contract negotiations – the cost consideration of clinical trials. As a result of these talks, these organizations have developed and published joint “Recommendations for the preparation of a total services calculation for remuneration related to the conduct of a clinical trial in a trial center” [2], [3]. The parties concerned share the conviction that, against the backdrops described, it would be helpful if the potential contract partners had access to recommendations that offer examples of constantly recurring cost positions in order to more precisely determine remuneration related to the conduct of a clinical trial. This article explains how the “Recommendations for the preparation of a total services calculation for remuneration related to the conduct of a clinical trial in a trial center” [2], [3] were developed and provides an overview of their content. German Medical Science GMS Publishing House 2019-10-24 /pmc/articles/PMC6838650/ /pubmed/31728135 http://dx.doi.org/10.3205/000276 Text en Copyright © 2019 Bruns et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bruns, Insa
Schade-Brittinger, Carmen
Wissing, Frank
Ruppert, Thorsten
Trillsch, Martin
Joint recommendations for a total services account as a factor in simplifying contracts
title Joint recommendations for a total services account as a factor in simplifying contracts
title_full Joint recommendations for a total services account as a factor in simplifying contracts
title_fullStr Joint recommendations for a total services account as a factor in simplifying contracts
title_full_unstemmed Joint recommendations for a total services account as a factor in simplifying contracts
title_short Joint recommendations for a total services account as a factor in simplifying contracts
title_sort joint recommendations for a total services account as a factor in simplifying contracts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838650/
https://www.ncbi.nlm.nih.gov/pubmed/31728135
http://dx.doi.org/10.3205/000276
work_keys_str_mv AT brunsinsa jointrecommendationsforatotalservicesaccountasafactorinsimplifyingcontracts
AT schadebrittingercarmen jointrecommendationsforatotalservicesaccountasafactorinsimplifyingcontracts
AT wissingfrank jointrecommendationsforatotalservicesaccountasafactorinsimplifyingcontracts
AT ruppertthorsten jointrecommendationsforatotalservicesaccountasafactorinsimplifyingcontracts
AT trillschmartin jointrecommendationsforatotalservicesaccountasafactorinsimplifyingcontracts